


**In the Claims**

Please add claim 32 and amend claim 31 as follows:

1. (Original) A compound a compound of formula I:



wherein:

R<sup>1</sup> is an organic releasing group comprising a quinone ring;

R<sub>a</sub>, R<sub>b</sub>, R<sub>c</sub>, and R<sub>d</sub> are each independently hydrogen, (C<sub>1</sub>-C<sub>6</sub>)alkyl, or -CH<sub>2</sub>CH<sub>2</sub>X;


and

each X is independently halo, (C<sub>1</sub>-C<sub>6</sub>)alkylsulfonyl, halo(C<sub>1</sub>-C<sub>6</sub>)alkylsulfonyl, or arylsulfonyl, wherein each aryl is optionally substituted with one or more (e.g. 1, 2, 3, or 4) halo, (C<sub>1</sub>-C<sub>6</sub>)alkyl, halo(C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, (C<sub>1</sub>-C<sub>6</sub>)alkanoyl, (C<sub>1</sub>-C<sub>6</sub>)alkanoyloxy, (C<sub>1</sub>-C<sub>6</sub>)alkoxycarbonyl, cyano, nitro, or trifluoromethoxy;

provided at least two of R<sub>a</sub>, R<sub>b</sub>, R<sub>c</sub>, and R<sub>d</sub> are -CH<sub>2</sub>CH<sub>2</sub>X;

or a pharmaceutically acceptable salt thereof.

2. (Original) The compound of claim 1 wherein R<sup>1</sup> is a group of formula (II):



wherein R<sub>e</sub> is hydrogen, halo, (C<sub>1</sub>-C<sub>6</sub>)alkyl, halo(C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, (C<sub>1</sub>-C<sub>6</sub>)alkanoyloxy, cyano, nitro, or (C<sub>1</sub>-C<sub>6</sub>)alkylthio; and

wherein the benz ring is optionally substituted by one or more (e.g. 1, 2, 3, or 4) hydroxy, halo, (C<sub>1</sub>-C<sub>6</sub>)alkyl, halo(C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, (C<sub>1</sub>-C<sub>6</sub>)alkylthio; (C<sub>1</sub>-C<sub>6</sub>)alkanoyl, (C<sub>1</sub>-C<sub>6</sub>)alkanoyloxy, (C<sub>1</sub>-C<sub>6</sub>)alkoxycarbonyl, cyano, nitro, mercapto, trifluoromethoxy, or NR<sub>f</sub>R<sub>g</sub>;

wherein each R<sub>f</sub> and R<sub>g</sub> is independently hydrogen, (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)alkanoyl, phenyl, benzyl, or phenethyl; or R<sub>f</sub> and R<sub>g</sub> together with the nitrogen to which they are attached are pyrrolidino, piperidino or morpholino.

3-4. (Cancelled).

5. (Original) The compound of claim 1 wherein X is bromo, chloro, mesyl, trifluoromethylsulfonyl, or tosyl.

6. (Original) The compound of claim 1 wherein X is bromo.

7. (Original) The compound of claim 2 wherein R<sub>c</sub> is hydrogen, halo, methyl, or methylthio.

8-11. (Cancelled).

12. (Original) The compound of claim 1 wherein R<sub>a</sub> is (C<sub>1</sub>-C<sub>6</sub>)alkyl.

13. (Original) The compound of claim 1 wherein R<sub>c</sub> is (C<sub>1</sub>-C<sub>6</sub>)alkyl.

14. (Original) The compound of claim 1 wherein R<sub>a</sub> and R<sub>b</sub> are each independently -CH<sub>2</sub>CH<sub>2</sub>X.

15. (Original) The compound of claim 1 wherein R<sub>c</sub>, and R<sub>d</sub> are each independently -CH<sub>2</sub>CH<sub>2</sub>X.

16. (Original) The compound of claim 1 wherein R<sub>b</sub> and R<sub>d</sub> are each independently -CH<sub>2</sub>CH<sub>2</sub>X.

17. (Original) The compound of claim 1 wherein R<sub>a</sub> is methyl.

18. (Original) The compound of claim 1 wherein  $R_c$  is methyl.
19. (Original) The compound of claim 1 wherein  $R_a$  and  $R_b$  are each  $-\text{CH}_2\text{CH}_2\text{Br}$ .
20. (Original) The compound of claim 1 wherein  $R_c$ , and  $R_d$  are each  $-\text{CH}_2\text{CH}_2\text{Br}$ .
21. (Original) The compound of claim 1 wherein  $R_b$  and  $R_d$  are each  $-\text{CH}_2\text{CH}_2\text{Br}$ .
22. (Original) The compound of claim 1 wherein  $R_a$  and  $R_b$  are each independently  $-\text{CH}_2\text{CH}_2\text{Cl}$ .
23. (Original) The compound of claim 1 wherein  $R_c$ , and  $R_d$  are each independently  $-\text{CH}_2\text{CH}_2\text{Cl}$ .
24. (Original) The compound of claim 1 wherein  $R_b$  and  $R_d$  are each independently  $-\text{CH}_2\text{CH}_2\text{Cl}$ .
25. (Previously Presented) The compound of claim 1 which is:  
2-(1,4-naphthoquinonyl)methyl *N,N*-bis(2-chloroethyl) phosphorodiamidate;  
2-(3-methyl-1,4-naphthoquinonyl)methyl *N,N*-bis(2-chloroethyl) phosphorodiamidate;  
2-(3-thiomethyl-1,4-naphthoquinonyl)methyl *N,N*-bis(2-chloroethyl)  
phosphorodiamidate;  
2-(3-bromo-1,4-naphthoquinonyl)methyl *N,N*-bis(2-chloroethyl) phosphorodiamidate;  
2-(1,4-naphthoquinonyl)methyl *N,N*-bis(2-bromoethyl) phosphorodiamidate;  
2-(3-methyl-1,4-naphthoquinonyl)methyl *N,N*-bis(2-bromoethyl) phosphorodiamidate;  
2-(1,4-naphthoquinonyl)methyl bis[*N*-(2-chloroethyl)] phosphorodiamidate;  
2-(1,4-naphthoquinonyl)methyl bis[*N*-methyl-*N*-(2-bromoethyl)]phosphorodiamidate;  
2-(3-methyl-1,4-naphthoquinonyl)methyl bis[*N*-methyl-*N*-(2-bromoethyl)]  
phosphorodiamidate;

2-(1,4-naphthoquinonyl)methyl bis[*N*-methyl-*N*-(2-chloroethyl)] phosphorodiamidate;  
or a pharmaceutically acceptable salt thereof.

26. (Cancelled).


27. (Original) A pharmaceutical composition comprising a compound of claim 1, in combination with a pharmaceutically acceptable diluent or carrier.

28. (Withdrawn) A therapeutic method for killing cancer cells or inhibiting their growth or proliferation comprising administering to a mammal in need of such therapy, an effective amount of a compound of claim 1.

29. (Withdrawn) The method of claim 28 wherein the cancer is a solid tumor.


30. (Cancelled).

31. (Currently amended) A method for preparing a compound of formula I as described in claim 1, wherein R<sup>1</sup> is a group of formula II



---

comprising oxidizing a corresponding compound of formula I wherein R<sup>1</sup> is a group of formula VI



32. (New) The compound of claim 1, wherein the organic releasing group is capable of releasing a group of formula  $-O-P(=O)(NR_aR_b)(NR_cR_d)$  *in vivo* from the compound of formula I.